134 related articles for article (PubMed ID: 36526493)
1. Re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3-5.
Tang Y; Hu X; Wu K; Shao Y; Li X
Eur Urol; 2023 Mar; 83(3):e73. PubMed ID: 36526493
[No Abstract] [Full Text] [Related]
2. Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li's Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3-5.
Capitanio U; Bedke J; Albiges L; Volpe A; Giles RH; Hora M; Marconi L; Klatte T; Abu-Ghanem Y; Dabestani S; Fernández Pello S; Hofmann F; Kuusk T; Campi R; Tahbaz R; Powles T; Ljungberg B; Bex A
Eur Urol; 2023 Mar; 83(3):e74-e75. PubMed ID: 36526491
[No Abstract] [Full Text] [Related]
3. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel.
Capitanio U; Bedke J; Albiges L; Volpe A; Giles RH; Hora M; Marconi L; Klatte T; Abu-Ghanem Y; Dabestani S; Fernández Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Ljungberg B; Bex A
Eur Urol; 2023 Jan; 83(1):3-5. PubMed ID: 36253306
[TBL] [Abstract][Full Text] [Related]
4. Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?
de Joode K; van der Veldt AAM
Eur Urol; 2020 Mar; 77(3):e76-e77. PubMed ID: 31610901
[No Abstract] [Full Text] [Related]
5. Reply to Yongbao Wei, Ruochen Zhang, and Le Lin's Letter to the Editor re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82:e88.
Ljungberg B; Bedke J; Capitanio U; Bex A
Eur Urol; 2022 Oct; 82(4):e111-e112. PubMed ID: 35773149
[No Abstract] [Full Text] [Related]
6. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
Wei Y; Zhang R; Lin L
Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
[No Abstract] [Full Text] [Related]
7. Re: Todd M. Morgan, Dominic Tang, Kelly L. Stratton, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011;59:923-8. Re: Umberto Capitanio, Francesco Montorsi. Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues. Eur Urol 2011;59:929-30.
Brookman-May S; Burger M; Wieland WF; May M
Eur Urol; 2011 Nov; 60(5):e45-6; author reply e47. PubMed ID: 21820239
[No Abstract] [Full Text] [Related]
8. Re: Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022;82:427-39.
Zhao B
Eur Urol; 2022 Dec; 82(6):e174-e175. PubMed ID: 36175267
[No Abstract] [Full Text] [Related]
9. Re: Nizar M. Tannir, Eric Jonasch, Laurence Albiges, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN):A Randomized Multicenter Phase 2 Trial. Eur Urol 2016;69:866-74.
Yang Z; Qi L; Chen M
Eur Urol; 2017 Jan; 71(1):e23-e24. PubMed ID: 27344295
[No Abstract] [Full Text] [Related]
10. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
11. Re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019:76:136-7.
Marconi L; Bensalah K; Bex A;
Eur Urol; 2019 Jul; 76(1):e12-e13. PubMed ID: 30922689
[No Abstract] [Full Text] [Related]
12. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100: Reply from the European Association of Urology Equity, Diversity, and Inclusion Task Force.
Carmen Mir M; Greenwell T; O'Kelly F; Proietti S; Laukhtina E; Mertens L; Morgenstern S; Ouzaid I;
Eur Urol; 2022 Jan; 81(1):e26-e27. PubMed ID: 34772550
[No Abstract] [Full Text] [Related]
13. Reply to Umberto Capitanio, Paolo Dell'Oglio, Alessandro Larcher, and Francesco Montorsi's Reply to Kazutaka Saito's Words of Wisdom re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a-T1b Renal Mass and Normal Preoperative Renal Function. Eur Urol. 2016;69:538.
Saito K
Eur Urol; 2016 Oct; 70(4):e99. PubMed ID: 27197698
[No Abstract] [Full Text] [Related]
14. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Takahashi T
Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251
[No Abstract] [Full Text] [Related]
15. Re: Vincent Cloutier, Umberto Capitanio, Laurent Zini, et al. Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur urol 2009;56:998-1005.
Campodonico F; Capponi G; Maffezzini M
Eur Urol; 2009 Dec; 56(6):e45-6; author reply e47. PubMed ID: 19307052
[No Abstract] [Full Text] [Related]
16. Reply to Lorenzo Marconi, Karim Bensalah, and Axel Bex's Letter to the Editor re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019;76:136-7.
Verhagen PCMS; Boevé ER
Eur Urol; 2019 Jul; 76(1):e14. PubMed ID: 30910344
[No Abstract] [Full Text] [Related]
17. Re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol. 2021;80:760-2: Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki.
Takahashi T
Eur Urol; 2022 Feb; 81(2):e44-e45. PubMed ID: 34887116
[No Abstract] [Full Text] [Related]
18. Reply to Takeshi Takahashi's Letter to the Editor re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol 2021;80;760-2. Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki: Re-envisioning the Value of Clinical Research to Foster the Progress of Evidence-based Urology: The Case of Partial Nephrectomy for cT2 Renal Masses.
Campi R; Bertolo R; Minervini A;
Eur Urol; 2022 Feb; 81(2):e46-e47. PubMed ID: 34887115
[No Abstract] [Full Text] [Related]
19. Re: Capitanio et al.: Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. (Urology 2008;72:1090-1095).
Chung SD; Chu SH; Tsai CC
Urology; 2009 Mar; 73(3):682-3; author reply 683-4. PubMed ID: 19248907
[No Abstract] [Full Text] [Related]
20. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100.
Dev S
Eur Urol; 2022 Jan; 81(1):e25. PubMed ID: 34663524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
